AstraZeneca Deploys High-Sensitivity Troponin Test As Brilinta Biomarker
In PLATO post hoc analysis, researchers correlate results on new, more sensitive heart damage test from Roche with positive outcomes for Brilinta in preventing events in patients who are managed medically as well as invasively.
You may also be interested in...
The company outlined plans to jumpstart growth of the anti-platelet drug Brilinta, including a 100% increase in marketing investment, increased rebates for payers and the addition of 200 nurse educators who will focus on the hospital discharge space.
AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.
U.S. physicians say skepticism over the North American results in the pivotal PLATO study is one of many factors that’s been slowing adoption. Competition with low-cost generics is another.